| Bioactivity | PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research[1][2]. |
| Invitro | PNC-28 (0-0.5 mg/mL) blocks growth of a lethal human pancreatic cancer cell line[2]. Cell Proliferation Assay[2] Cell Line: |
| In Vivo | PNC-28 (2 mg/mouse, SC or IP, for 14 days) blocks the growth of BMRPA1. Tuc3 cells in vivo[1].PNC-28 (1-20 mg/mouse, SC, for 14 days) inhibits BMRPA1. Tuc3 tumor growth especially if delivered directly to the tumor [1]. Animal Model: |
| Name | PNC-28 |
| CAS | 392661-17-5 |
| Shortening | ETFSDLWKLLKKWKMRRNQFWVKVQRG |
| Formula | C164H255N47O37S |
| Molar Mass | 3509.13 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Michl J, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006 Oct 1;119(7):1577-85. [2]. Kelley A. Sookraj. QS304. Novel p53-Derived Peptide Induces Rapid Human Pancreatic Cancer Cell Death. 2008, 144(2), 1. |
PNC-28
CAS: 392661-17-5 F: C164H255N47O37S W: 3509.13
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossin
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.